Skip to content

EchoNavigator 3D Models

EchoNavigator R3 Investigational Device; The Clinical Value of 3D TEE Models for Structural Heart Disease Procedures

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON24577
Enrollment
30
Registered
2016-03-11
Start date
2016-05-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Structural Heart Disease procedures: LAAC, TMVR and TAVI

Interventions

No interventions to the normal way of working in the protocol, study is observational.

Sponsors

Philips Medical Systems B.V.
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients that require one of the following SHD interventions for which routine fluoroscopy and TEE guidance is used: MitraClip placement on the mitral valve (TMVR), left atrial appendage closure (LAAC), trans catheter aortic valve implantation (TAVI) • Subject is 18 years of age or older, or of legal age to give informed consent per state or national law

Exclusion criteria

Exclusion criteria: -Patients who are unsuitable to accept TEE imaging during a SHD intervention, further descibed in the Clinical Research Plan. -Subject participates in a potentially confounding drug or device trial during the course of the study. -Subject meets an exclusion criteria according to national law (e.g. Age, pregnant woman, breast feeding woman)

Design outcomes

Secondary

MeasureTime frame
Secondary endpoints are qualitative feedback on the user interfaceto improve the investigational device, eecorded anonymized raw Echo and X-ray data to tune algorithm parameters and qualitative to improve future versions of the EchoNavigator device.

Primary

MeasureTime frame
The primary endpoint is a qualitative and quantitative assessment by comparing the distances between annotations genered automatically by the model with manual annotated structures and/or validating the position of the annotations by contrast enhanced X-ray angio or the location of X-ray opaque structures (e.g. devices) on the X-ray image.

Contacts

Public ContactRoberto Corti

Department of Cardiology - HerzKlinik Hirsianden

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)